IMPORTANCE: Patients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in CM-MOH. OBJECTIVE: To assess erenumab efficacy and safety in patients with nonopioid CM-MOH. DESIGN, SETTINGS, AND PARTICIPANTS: This randomized, double-blind, parallel-group, placebo-controlled trial took place at 67 centers in North America, Europe, and Australia from October 7, 2019, to November 2, 2022. This report reflects the primary analysis conducted in January 2023, using a database snapshot from December 1, 2022, which contains the complete dataset of the double-blind treatment period (DBTP). Participants included adults with CM-MOH who had 1 or more preventive treatment failure(s). There were 992 participants screened and 620 participants enrolled (584 in nonopioid cohort and 36 in opioid cohort). INTERVENTIONS: Erenumab, 70 mg, 140 mg, or placebo, once monthly for 24 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was MOH remission at month 6. Secondary end points included change from baseline in mean monthly acute headache medication days (AHMD) at month 6 and sustained MOH remission throughout the DBTP. Safety end points were adverse events and changes in vital signs. RESULTS: The primary analysis population included 584 participants in the nonopioid-treated cohort with a mean age of 44 years and 482 participants were female (82.5%). Baseline demographics and disease characteristics were balanced across groups. At month 6, 134 participants in the erenumab, 140 mg group (69.1%) (odds ratio [OR], 2.01; 95% CI, 1.33-3.05; P < .001 vs placebo) and 117 in the erenumab, 70 mg group (60.3%) (OR, 1.37; 95% CI, 0.92-2.05; P = .13 vs placebo) achieved MOH remission vs 102 participants in the placebo group (52.6%). AHMD use was also reduced in the erenumab groups vs placebo. Least squares mean (standard error) change from baseline in average monthly AHMD was -9.4 (0.4) days in the erenumab, 140 mg group (difference from placebo, -2.7; 95% CI, -3.9 to -1.6; P < .001) and -7.8 (0.4) days in the erenumab, 70 mg group (difference from placebo, -1.2; 95% CI, -2.4 to -0.1; P = .03), vs -6.6 (0.4) days in the placebo group. MOH remission throughout the DBTP was sustained in 119 participants (61.3%,) 96 participants (49.5%), and 73 participants (37.6%) in the erenumab, 140 mg, 70 mg, and placebo groups, respectively. Adverse events were consistent with the known safety profile of erenumab. Treatment-emergent adverse events incidence in the combined erenumab group was 66.8% (259 participants; constipation 15.2% (59 participants) and COVID-19 13.9% (54 participants) were most common. CONCLUSIONS AND RELEVANCE: In this study, monthly, 140 mg, erenumab injections safely and effectively achieved MOH remission in patients with nonopioid CM-MOH within 6 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03971071.

Amgen Inc Thousand Oaks California

Atria Academy of Science and Medicine New York New York

Center for Interdisciplinary Research in Health Universidade Católica Portuguesa Lisboa Portugal

Department of Neurology Mayo Clinic Scottsdale Arizona

Department of Neurology Poznan University of Medical Sciences Poznan Poland

Department of Pain CHU Lille France

Inserm U1107 Neuro Dol Université Clermont Auvergne Clermont Ferrand France

Neurology Department Hospital da Luz Luz Saude Lisboa Portugal

Óbudai Egészségügyi Centrum Budapest Hungary

Pain Department and FHU InovPain Centre Hospitalier Universitaire de Nice Côte Azur and University Nice France

Prague Headache Center DADO MEDICAL sro Prague Czech Republic

The New England Institute for Neurology and Headache Stamford Connecticut

Zobrazit více v PubMed

Raggi A, Schiavolin S, Leonardi M, et al. . Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients’ lives. J Neurol Sci. 2015;348(1-2):60-66. doi:10.1016/j.jns.2014.11.004 PubMed DOI

Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575-583. doi:10.1038/nrneurol.2016.124 PubMed DOI

Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5(2):87-99. doi:10.1177/2042098614522683 PubMed DOI PMC

Schwedt TJ, Buse DC, Argoff CE, et al. . Medication overuse and headache burden: results from the CaMEO study. Neurol Clin Pract. 2021;11(3):216-226. doi:10.1212/CPJ.0000000000001037 PubMed DOI PMC

Headache Classification Committee of the International Headache Society . Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders; 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202 PubMed DOI

Schwedt TJ, Sahai-Srivastava S, Murinova N, et al. ; MOTS Investigators . Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: results from the MOTS trial. Cephalalgia. 2021;41(10):1053-1064. doi:10.1177/03331024211006903 PubMed DOI

Suh GI, Park JW, Shin HE. Differences in clinical features and disability according to the frequency of medication use in patients with chronic migraine. J Clin Neurol. 2012;8(3):198-203. doi:10.3988/jcn.2012.8.3.198 PubMed DOI PMC

Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol. 2012;25(3):290-295. doi:10.1097/WCO.0b013e328352c431 PubMed DOI

Linde M, Gustavsson A, Stovner LJ, et al. . The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703-711. doi:10.1111/j.1468-1331.2011.03612.x PubMed DOI

Vandenbussche N, Laterza D, Lisicki M, et al. . Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018;19(1):50. doi:10.1186/s10194-018-0875-x PubMed DOI PMC

Carlsen LN, Munksgaard SB, Nielsen M, et al. . Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 2020;77(9):1069-1078. doi:10.1001/jamaneurol.2020.1179 PubMed DOI PMC

Goadsby PJ, Reuter U, Hallström Y, et al. . A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132. doi:10.1056/NEJMoa1705848 PubMed DOI

Dodick DW, Ashina M, Brandes JL, et al. . ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026-1037. doi:10.1177/0333102418759786 PubMed DOI

Tepper SJ, Diener HC, Ashina M, et al. . Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309-e2320. doi:10.1212/WNL.0000000000007497 PubMed DOI PMC

Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain. 2020;21(1):114. doi:10.1186/s10194-020-01173-8 PubMed DOI PMC

Tepper SJ, Lipton RB, Silberstein SD, et al. . Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: a subgroup analysis. Headache. 2023;63(6):730-742. doi:10.1111/head.14536 PubMed DOI

Dodick DW, Doty EG, Aurora SK, et al. . Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021;41(3):340-352. doi:10.1177/0333102420966658 PubMed DOI

Diener HC, Marmura MJ, Tepper SJ, et al. . Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache. 2021;61(1):125-136. doi:10.1111/head.14036 PubMed DOI

Yu S, Zhou J, Luo G, et al. . Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study. BMC Neurol. 2023;23(1):441. doi:10.1186/s12883-023-03477-z PubMed DOI PMC

Tepper SJ, Dodick DW, Lucas S, et al. . 62(nd) Annual Scientific Meeting American Headache Society((R)). Efficacy of erenumab in chronic migraine patients with acute headache medication overuse: a post hoc analysis assessing outcomes using different definitions of remission. Headache. 2020;60(suppl 1):1-156. doi:10.1111/head.13854 PubMed DOI

Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. ; MOTS Investigators . Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021;61(2):351-362. doi:10.1111/head.14056 PubMed DOI

de Goffau MJ, Klaver ARE, Willemsen MG, Bindels PJE, Verhagen AP. The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain. 2017;18(6):615-627. doi:10.1016/j.jpain.2016.12.005 PubMed DOI

Rossi P, Faroni JV, Tassorelli C, Nappi G. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain. 2013;14(1):10. doi:10.1186/1129-2377-14-10 PubMed DOI PMC

Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28(2):152-156. doi:10.1111/j.1468-2982.2007.01488.x PubMed DOI

Bøe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology. 2007;69(1):26-31. doi:10.1212/01.wnl.0000263652.46222.e8 PubMed DOI

Taghdiri F, Togha M, Razeghi Jahromi S, Paknejad SM. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. 2015;55(1):128-135. doi:10.1111/head.12487 PubMed DOI

Arab A, Khoshbin M, Karimi E, Saberian G, Saadatnia M, Khorvash F. Effects of greater occipital nerve block with local anesthetic and triamcinolone for treatment of medication overuse headache: an open-label, parallel, randomized, controlled clinical trial. Neurol Sci. 2022;43(1):549-557. doi:10.1007/s10072-021-05295-y PubMed DOI

Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: an entrenched idea in need of scrutiny. Neurology. 2017;89(12):1296-1304. doi:10.1212/WNL.0000000000004371 PubMed DOI

Reuter U, Ehrlich M, Gendolla A, et al. . Erenumab versus topiramate for the prevention of migraine—a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108-118. doi:10.1177/03331024211053571 PubMed DOI PMC

Robblee J, Hakim SM, Reynolds JM, Monteith TS, Zhang N, Barad M. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: a systematic review and meta-analysis of randomized controlled trials. Headache. 2024;64(5):547-572. doi:10.1111/head.14693 PubMed DOI

Pozo-Rosich P, Dolezil D, Paemeleire K, et al. . Early use of erenumab vs nonspecific oral migraine preventives: the APPRAISE randomized clinical trial. JAMA Neurol. 2024;81(5):461-470. doi:10.1001/jamaneurol.2024.0368 PubMed DOI PMC

Gil-Gouveia R, Dolezil D, Paemeleire K, et al. . Abstracts of the 8(th) Congress of the European Academy of Neurology, Vienna, Austria. Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from the APPRAISE study. Eur J Neurol. 2022;29(suppl 1):6-918. doi:10.1111/ene.15461 PubMed DOI

Kopruszinski CM, Xie JY, Eyde NM, et al. . Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia. 2017;37(6):560-570. doi:10.1177/0333102416650702 PubMed DOI

Caronna E, José Gallardo V, Alpuente A, et al. ; Spanish CGRP-COVID Study Group . Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications. Neurologia (Engl Ed). 2021;36(8):611-617. doi:10.1016/j.nrl.2021.03.003 PubMed DOI PMC

Tepper SJ, Sheikh HU, Dougherty CO, et al. . Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations. Headache. 2022;62(4):420-435. doi:10.1111/head.14266 PubMed DOI

Tepper SJ, Cirillo J, Kim E, et al. . The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. J Headache Pain. 2023;24(1):54. doi:10.1186/s10194-023-01587-0 PubMed DOI PMC

Forbes RB, McCarron M, Cardwell CR. Efficacy and contextual (placebo) effects of CGRP antibodies for migraine: systematic review and meta-analysis. Headache. 2020;60(8):1542-1557. doi:10.1111/head.13907 PubMed DOI

Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006;66(12):1894-1898. doi:10.1212/01.wnl.0000217914.30994.bd PubMed DOI

Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia. 2018;38(2):225-236. doi:10.1177/0333102417737779 PubMed DOI

Ashina S, Terwindt GM, Steiner TJ, et al. . Medication overuse headache. Nat Rev Dis Primers. 2023;9(1):5. doi:10.1038/s41572-022-00415-0 PubMed DOI

Wang K, Fenton BT, Deng Y, et al. . Calcitonin gene-related peptide monoclonal antibodies and risk of SARS-CoV-2 infection and severe COVID-19 outcomes among veterans with migraine disorder. JAMA Netw Open. 2023;6(7):e2326371. doi:10.1001/jamanetworkopen.2023.26371 PubMed DOI PMC

Pascual J, Núñez M, Panni T, Díaz-Cerezo S, Novick D, Ciudad A. Burden and unmet needs in migraine patients: results from the OVERCOME (Spain) study. Pain Ther. 2023;12(5):1209-1220. doi:10.1007/s40122-023-00538-6 PubMed DOI PMC

Lipton RB, Nicholson RA, Reed ML, et al. . Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62(2):122-140. doi:10.1111/head.14259 PubMed DOI PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03971071